Marker Therapeutics Stock Buy Hold or Sell Recommendation
| MRKR Stock | USD 4.43 0.24 5.73% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Marker Therapeutics is 'Strong Sell'. Macroaxis provides Marker Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding MRKR positions. The advice algorithm takes into account all of Marker Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Marker Therapeutics' buy or sell advice are summarized below:
Real Value 13.13 | Target Price 40 | Hype Value 4.43 | Market Value 4.43 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Marker Therapeutics given historical horizon and risk tolerance towards Marker Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Marker Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Marker |
Execute Marker Therapeutics Buy or Sell Advice
The Marker recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Marker Therapeutics. Macroaxis does not own or have any residual interests in Marker Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Marker Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Marker Therapeutics Trading Alerts and Improvement Suggestions
| Marker Therapeutics had very high historical volatility over the last 90 days | |
| Marker Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M). | |
| Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Marker Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Is Marker Therapeutics In A Good Position To Invest In Growth - Yahoo Movies Canada |
Marker Therapeutics Returns Distribution Density
The distribution of Marker Therapeutics' historical returns is an attempt to chart the uncertainty of Marker Therapeutics' future price movements. The chart of the probability distribution of Marker Therapeutics daily returns describes the distribution of returns around its average expected value. We use Marker Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Marker Therapeutics returns is essential to provide solid investment advice for Marker Therapeutics.
| Mean Return | 0.02 | Value At Risk | -6.25 | Potential Upside | 5.82 | Standard Deviation | 3.71 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Marker Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Marker Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Marker Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Marker Therapeutics backward and forwards among themselves. Marker Therapeutics' institutional investor refers to the entity that pools money to purchase Marker Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2023-12-31 | 6.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3.6 K | Bank Of America Corp | 2023-12-31 | 2.3 K | Riggs Asset Management Co Inc | 2023-12-31 | 1.6 K | Blackrock Inc | 2023-12-31 | 1.4 K | Tower Research Capital Llc | 2023-12-31 | 1.3 K | International Assets Investment Management, Llc | 2023-09-30 | 1000 | U.s. Bancorp | 2023-12-31 | 839 | Wells Fargo & Co | 2023-12-31 | 283 | Nea Management Company, Llc | 2023-12-31 | 1.1 M | Aisling Capital Management Lp | 2023-12-31 | 314.3 K |
Marker Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (17.8M) | (22.6M) | 22.1M | (31.7M) | 3.3M | 3.5M | |
| Free Cash Flow | (18.7M) | (29.3M) | (30.4M) | (31.9M) | (16.4M) | (15.6M) | |
| Other Non Cash Items | (18K) | (31K) | 7.1M | (252.7K) | (6.1M) | (5.8M) | |
| Net Income | (21.4M) | (28.7M) | (41.9M) | (29.9M) | (14.0M) | (14.7M) | |
| End Period Cash Flow | 43.9M | 21.4M | 43.5M | 11.8M | 15.1M | 10.0M | |
| Change To Netincome | 132.4M | 5.3M | 5.2M | 6.0M | 6.9M | 6.5M | |
| Investments | (375.0K) | (10.4M) | (3.1M) | (4.9M) | 18.5M | 19.5M |
Marker Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Marker Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Marker Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Marker stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.03 | |
β | Beta against NYSE Composite | -0.25 | |
σ | Overall volatility | 3.72 | |
Ir | Information ratio | -0.02 |
Marker Therapeutics Volatility Alert
Marker Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Marker Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Marker Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Marker Therapeutics Fundamentals Vs Peers
Comparing Marker Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Marker Therapeutics' direct or indirect competition across all of the common fundamentals between Marker Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Marker Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Marker Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Marker Therapeutics to competition |
| Fundamentals | Marker Therapeutics | Peer Average |
| Return On Equity | -0.83 | -0.31 |
| Return On Asset | -0.35 | -0.14 |
| Profit Margin | (2.49) % | (1.27) % |
| Operating Margin | (2.78) % | (5.51) % |
| Current Valuation | 22.19 M | 16.62 B |
| Shares Outstanding | 8.9 M | 571.82 M |
| Shares Owned By Insiders | 12.16 % | 10.09 % |
| Shares Owned By Institutions | 22.90 % | 39.21 % |
| Number Of Shares Shorted | 107.89 K | 4.71 M |
| Price To Earning | (9.39) X | 28.72 X |
| Price To Book | 2.73 X | 9.51 X |
| Price To Sales | 11.59 X | 11.42 X |
| Revenue | 3.31 M | 9.43 B |
| Gross Profit | (17.13 M) | 27.38 B |
| EBITDA | (14.58 M) | 3.9 B |
| Net Income | (14.05 M) | 570.98 M |
| Cash And Equivalents | 18.08 M | 2.7 B |
| Cash Per Share | 0.22 X | 5.01 X |
| Total Debt | 7.62 M | 5.32 B |
| Debt To Equity | 0.34 % | 48.70 % |
| Current Ratio | 1.99 X | 2.16 X |
| Book Value Per Share | 1.58 X | 1.93 K |
| Cash Flow From Operations | (16.44 M) | 971.22 M |
| Short Ratio | 5.22 X | 4.00 X |
| Earnings Per Share | (1.59) X | 3.12 X |
| Target Price | 12.5 | |
| Number Of Employees | 8 | 18.84 K |
| Beta | 1.54 | -0.15 |
| Market Capitalization | 37.3 M | 19.03 B |
| Total Asset | 17.13 M | 29.47 B |
| Retained Earnings | (436.29 M) | 9.33 B |
| Working Capital | 14.05 M | 1.48 B |
| Current Asset | 6.85 M | 9.34 B |
Note: Acquisition by Makhzoumi Mohamad of 5714285 shares of Marker Therapeutics at 1.75 subject to Rule 16b-3 [view details]
Marker Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Marker . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Marker Therapeutics Buy or Sell Advice
When is the right time to buy or sell Marker Therapeutics? Buying financial instruments such as Marker Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 11.9M | 7.6M | 8.8M | 9.2M | Total Assets | 68.1M | 34.4M | 17.1M | 13.6M |
Use Investing Ideas to Build Portfolios
In addition to having Marker Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Restaurants Thematic Idea Now
Restaurants
Entities that are involved in restaurant business, as well as coffee shop chains and other eateries. The Restaurants theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaurants Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Marker Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Marker Stock analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stocks Directory Find actively traded stocks across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Marker Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.376 | Quarterly Revenue Growth 0.392 | Return On Assets (0.35) | Return On Equity (0.83) |
The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.